Trial Profile
A 6-month, multicenter, randomized, open-label study of safety and efficacy of everolimus-based regimen versus calcineurin inhibitor-based regimen in maintenance liver transplant recipients
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Everolimus (Primary) ; Ciclosporin; Tacrolimus
- Indications Liver transplant rejection
- Focus Adverse reactions; Registrational
- Acronyms RESCUE
- Sponsors Novartis
- 01 Oct 2009 Results published in Liver Transplantation.
- 18 Aug 2009 Actual end date (Nov 2007) added as reported by ClinicalTrials.gov.
- 03 Jun 2009 Results were reported at the American Transplant Congress -- 9th Joint Congress of the American Society of Transplant Surgeons (ASTS) and the American Society of Transplantation (AST).